Search Results - "Jeng, Philip J"

Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration by Cadet, Techna, Jalali, Ali, Jeng, Philip J, Poole, Sabrina, Woody, George, Murphy, Sean M

“…BACKGROUND\OBJECTIVES: Concomitant with low rates of pharmacotherapy for incarcerated individuals with OUD, there is a high rate of opioid overdose following…”
Get full text

Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services Knowledge-PrEP (A.S.K.-PrEP) by Reback, Cathy J, Landovitz, Raphael J, Benkeser, David, Jalali, Ali, Shoptaw, Steven, Li, Michael J, Mata, Raymond P, Ryan, Danielle, Jeng, Philip J, Murphy, Sean M

“…Abstract Background In the United States, most (~ 70%) annual newly diagnosed HIV infections are among substance-using sexual minority men (SMM) and gender…”
Get full text

Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials by Murphy, Sean M, Jeng, Philip J, Poole, Sabrina A, Jalali, Ali, Vocci, Frank J, Gordon, Michael S, Woody, George E, Polsky, Daniel

“…Persons with an opioid use disorder (OUD) who were incarcerated face many challenges to remaining abstinent; concomitantly, opioid-overdose is the leading…”
Get full text

Prescription Drug Monitoring Program Mandates: Impact On Opioid Prescribing And Related Hospital Use by Wen, Hefei, Hockenberry, Jason M., Jeng, Philip J., Bao, Yuhua

“…Comprehensive mandates for prescription drug monitoring programs (PDMPs) require state-licensed prescribers and dispensers both to register with and to use the…”
Get full text

The role of increasing pharmacy and community distributed naloxone in the opioid overdose epidemic in Massachusetts, Rhode Island, and New York City by Morgan, Jake R., Freibott, Christina E., Jalali, Ali, Jeng, Philip J., Walley, Alexander Y., Chatterjee, Avik, Green, Traci C., Nolan, Michelle L., Linas, Benjamin P., Marshall, Brandon D.L., Murphy, Sean M.

“…•Role of pharmacy-distributed naloxone in population-level overdose death is unknown.•We linked pharmacy and community distributed naloxone to overdose and…”
Get full text

Association between jail‐based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17 by Lim, Sungwoo, Cherian, Teena, Katyal, Monica, Goldfeld, Keith S., McDonald, Ryan, Wiewel, Ellen, Khan, Maria, Krawczyk, Noa, Braunstein, Sarah, Murphy, Sean M., Jalali, Ali, Jeng, Philip J., MacDonald, Ross, Lee, Joshua D.

“…Background and aims Opioid overdose is a leading cause of death during the immediate time after release from jail or prison. Most jails in the United States do…”
Get full text

State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals by Kapadia, Shashi N, Jeng, Philip J, Schackman, Bruce R, Bao, Yuhua

“…Medicaid program criteria for accessing hepatitis C treatment are changing. Medicaid drug utilization data from 2014 to 2016 show that programs that have…”
Get full text

State Policies for Prescription Drug Monitoring Programs and Adverse Opioid-related Hospital Events by Wen, Katherine, Johnson, Phyllis, Jeng, Philip J., Schackman, Bruce R., Bao, Yuhua

“…BACKGROUND:State policies to optimize prescriber use of Prescription Drug Monitoring Programs (PDMPs) have proliferated in recent years. Prominent policies…”
Get full text

Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid Prescriptions by Bao, Yuhua, Wen, Katherine, Johnson, Phyllis, Jeng, Philip J, Meisel, Zachary F, Schackman, Bruce R

“…Policies and practices have proliferated to optimize prescribers' use of their states' prescription drug monitoring programs, which are statewide databases of…”
Get full text

Will converting naloxone to over‐the‐counter status increase pharmacy sales? by Murphy, Sean M., Morgan, Jake R., Jeng, Philip J., Schackman, Bruce R.

“…Objective To estimate the own‐price elasticity of demand for naloxone, a prescription medication that can counter the effects of an opioid overdose, and…”
Get full text

Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse by Murphy, Sean M, McCollister, Kathryn E, Leff, Jared A, Yang, Xuan, Jeng, Philip J, Lee, Joshua D, Nunes, Edward V, Novo, Patricia, Rotrosen, John, Schackman, Bruce R

“…Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder. To evaluate the…”
Get full text

Robust Prescription Monitoring Programs and Abrupt Discontinuation of Long-term Opioid Use by Bao, Yuhua, Zhang, Hao, Wen, Katherine, Johnson, Phyllis, Jeng, Philip J., Witkin, Lisa R., Nicholson, Sean, Reid, M. Carrington, Schackman, Bruce R.

“…This study assesses the associations between the recent implementation of robust features of state Prescription Drug Monitoring Programs and the abrupt…”
Get full text

Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration by Cherian, Teena, Lim, Sungwoo, Katyal, Monica, Goldfeld, Keith S., McDonald, Ryan, Wiewel, Ellen, Khan, Maria, Krawczyk, Noa, Braunstein, Sarah, Murphy, Sean M., Jalali, Ali, Jeng, Philip J., Rosner, Zachary, MacDonald, Ross, Lee, Joshua D.

“…Non-fatal overdose is a leading predictor of subsequent fatal overdose. For individuals who are incarcerated, the risk of experiencing an overdose is highest…”
Get full text

Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study by Krawczyk, Noa, Lim, Sungwoo, Cherian, Teena, Goldfeld, Keith S., Katyal, Monica, Rivera, Bianca D., McDonald, Ryan, Khan, Maria, Wiewel, Ellen, Braunstein, Sarah, Murphy, Sean M., Jalali, Ali, Jeng, Philip J., Kutscher, Eric, Khatri, Utsha G., Rosner, Zachary, Vail, William L., MacDonald, Ross, Lee, Joshua D.

“…Offering medications for opioid use disorder (MOUD) in carceral settings significantly reduces overdose. However, it is unknown to what extent individuals in…”
Get full text

State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients by Zhang, Hao, Tallavajhala, Srikar, Kapadia, Shashi N., Jeng, Philip J., Shi, Yuyan, Wen, Hefei, Bao, Yuhua

“…BACKGROUND:Since early 2016, an increasing number of states passed legislations that limit the duration and/or dosage of initial opioid prescriptions or…”
Get full text

The Learning Curve After Implementation of Collaborative Care in a State Mental Health Integration Program by Carlo, Andrew D, Jeng, Philip J, Bao, Yuhua, Unützer, Jürgen

“…Objective:This study examined organizational variability of process-of-care and depression outcomes at eight community health centers (CHCs) in the years…”
Get full text

Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019 by Chatterjee, Avik, Yan, Shapei, Lambert, Audrey, Morgan, Jake R, Green, Traci C, Jeng, Philip J, Jalali, Ali, Xuan, Ziming, Krieger, Maxwell, Marshall, Brandon D L, Walley, Alexander Y, Murphy, Sean M

“…Accurate naloxone distribution data are critical for planning and prevention purposes, yet sources of naloxone dispensing data vary by location, and…”
Get full text

Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial by Jalali, Ali, Ryan, Danielle A., Jeng, Philip J., McCollister, Kathryn E., Leff, Jared A., Lee, Joshua D., Nunes, Edward V., Novo, Patricia, Rotrosen, John, Schackman, Bruce R., Murphy, Sean M.

“…•Health-Related Quality of Life (HRQoL) can be classified into two longitudinal subpopulations.•HRQoL may be improved through the use of pharmacotherapy for…”
Get full text

Cost‐effectiveness implications of increasing the efficiency of the extended‐release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis by Murphy, Sean M., Jeng, Philip J., McCollister, Kathryn E., Leff, Jared A., Jalali, Ali, Shulman, Matisyahu, Lee, Joshua D., Nunes, Edward V., Novo, Patricia, Rotrosen, John, Schackman, Bruce R.

“…Background and Aims In a US randomized‐effectiveness trial comparing extended‐release naltrexone (XR‐NTX) with buprenorphine–naloxone (BUP‐NX) for the…”
Get full text

Design of a Payment Decision–Support Tool for Coordinated Specialty Care for Early Psychosis by Bao, Yuhua, Li, Yan, Jeng, Philip J, Scodes, Jennifer, Papp, Michelle A, Humensky, Jennifer L, Wall, Melanie, Lee, Rufina, Ancker, Jessica S, Pincus, Harold Alan, Smith, Thomas E, Dixon, Lisa B

“…A strengthened evidence base and earmarked federal funding have spurred the implementation of coordinated specialty care (CSC) for people experiencing early…”
Get full text